Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.

Objectives. Pharmacokinetics studies recommend increasing efavirenz dosage in tuberculosis/HIV patients using rifampicin. We aimed to evaluate efficacy and safety of 600 versus 800 mg of efavirenz in tuberculosis/HIV patients using rifampicin. Design. We conducted an open label, multicentre, randomi...

Descripción completa

Detalles Bibliográficos

Publicado en:	BioMed Research International pp. 1 - 12
Autores principales:	Xavier, Mariana S., Trajman, Anete, Schmaltz, Carolina A. S., Sant'anna, Flavia M., Maia, Ivan R., Hadad, David J., Brasil, Pedro Emmanuel A. A. do, Rolla, Valeria
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Wiley-Blackwell 12/25/2018
Acceso en línea:	Ver este registro en EBSCOhost